Contact
Please use this form to send email to PR contact of this press release:
Shield Therapeutics plc ("Shield" or the "Group") US Composition of Matter Patent
TO:
Please use this form to send email to PR contact of this press release:
Shield Therapeutics plc ("Shield" or the "Group") US Composition of Matter Patent
TO: